Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD Pharmaceutical TechnologyOutlook's approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD. Ophthalmology Read full story Post navigation Previous: D.C. Circuit Affirms HHS Authority Over 340B Rebate ModelsNext: Outlook finally claims FDA approval for AMD drug Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026